Riechelmann H et al. |
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. |
2008 |
Oral Oncol. |
pmid:18203652
|
Montero JC et al. |
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. |
2015 |
Oncotarget |
pmid:26336133
|
Nonagase Y et al. |
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. |
2016 |
Oncotarget |
pmid:27768588
|
Raja SM et al. |
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. |
2016 |
Oncotarget |
pmid:26859680
|
Pegram M |
Treatment combinations for HER2-positive breast cancer. |
2013 |
Oncology (Williston Park, N.Y.) |
pmid:23781688
|
Ranson M and Sliwkowski MX |
Perspectives on anti-HER monoclonal antibodies. |
2002 |
Oncology |
pmid:12422051
|
Mujagić H and Mujagić Z |
Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton. |
1991 |
Oncology |
pmid:2023698
|
Lynce F et al. |
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. |
2017 |
Oncologist |
pmid:28314836
|
Kan S et al. |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. |
2015 |
Oncol. Rep. |
pmid:25976081
|
Yamashita-Kashima Y et al. |
Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. |
2013 |
Oncol. Rep. |
pmid:23783223
|